Schonfeld Strategic Advisors 13F: Adds $22M to BSX Stake
Schonfeld Strategic Advisors raised its stake in Boston Scientific Corporation by more than 84% during the period ended May 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Schonfeld Strategic Advisors added 506,234 shares to its stake in Boston Scientific Corporation ($BSX), an 84.47% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 1,105,515 shares worth $47.10 million at the end of the quarter.
Since the filing, $BSX is up 9.7% after 1 week, down 11.2% after 1 month and down 15.7% to date (from the $52.68 close on May 15, 2026).
Find the original: Schonfeld Strategic Advisors 13F filings on SEC EDGAR
BSX
Boston Scientific Corporation
Key Points
- Schonfeld Strategic Advisors lifted its stake in Boston Scientific Corporation NYSE:BSX by 84.5% during the period ended May 15, 2026.
- The fund added 506,234 shares to bring its total holding to 1,105,515 shares with a reported value of about $47.1 million.
- Boston Scientific trades with a P/E ratio of 17.9 and has a next earnings date scheduled for October 28, 2026.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Schonfeld Strategic Advisors Grows Stake in Boston Scientific
Schonfeld Strategic Advisors raised its investment in Boston Scientific Corporation NYSE:BSX, according to a Form 13F filing with the U.S. Securities and Exchange Commission for the period ended May 15, 2026. The filing reveals that the fund boosted its position by picking up hundreds of thousands of additional shares in the medical device maker.
Inside the Fund's 84.5% Increase
The fund added 506,234 shares during the period, marking an 84.47% increase to its prior holdings. Schonfeld ended the period with 1,105,515 shares of Boston Scientific. The value of the position stood at approximately $47.1 million based on the reported figures. Because 13F filings look backward at portfolio choices from the close of the quarter, these numbers show past positioning and might not match the fund's current holdings today.
Boston Scientific Stock Performance
The stock recently changed hands around $42.60 per share, moving within a 52-week range that spans from a low of $41.39 to a high of $105.65. The company carries a market capitalization of roughly $64.0 billion and a price-to-earnings ratio of 17.9. Investors should remember that 13F data only captures a snapshot of institutional ownership from past months.
Recent Earnings and Financial Health
Boston Scientific generated annual revenue of $21.0 billion, translating to revenue growth of 7.5%. The company posted earnings of $2.47 per share alongside a net margin of 17.5% and a return on equity of 15.3%. The firm is scheduled to report its next round of financial results on October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Wall Street Analyst Updates
Wall Street firms have kept a close eye on the medical device maker with a mix of ratings and price targets. On October 14, 2026, Truist Securities maintained a Buy rating while moving its price target from $57.00 to $51.00. Earlier on October 7, 2026, Barclays initiated coverage with an Equal-Weight rating and a $48.00 price target. Citigroup maintained a Neutral rating on October 5, 2026, and lowered its target to $48.00.
About Boston Scientific Corporation
Boston Scientific develops and sells medical devices used in interventional medical specialties across the globe. The enterprise operates through two core segments, MedSurg and Cardiovascular, offering products that treat gastrointestinal conditions, urological disorders, neurological issues, and cardiac rhythm abnormalities. Headquartered in Marlborough, Massachusetts, the firm employs tens of thousands of workers worldwide.
What to Watch at Boston Scientific Corporation
Investors tracking Schonfeld Strategic Advisors will look to subsequent quarterly disclosures to see whether the fund maintains or alters its position. Market participants can also anticipate fresh revenue and margin data when the company releases its earnings report in late October. As always, these regulatory filings offer a historical look at institutional moves rather than an active trading signal.
Related Filing Alerts
Source: Schonfeld Strategic Advisors's 13F filing on $BSX (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Schonfeld Strategic Advisors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts